Patient-, disease-, and transplantation-related characteristics
Variable . | No. (%)* . |
|---|---|
| Patient characteristics | |
| Younger than 40 y | 158 (68) |
| 40 y or older | 75 (32) |
| Male sex | 150 (64) |
| Disease characteristics at diagnosis | |
| Histology | |
| Indolent | 38 (16) |
| Follicular | 37 (16) |
| MALT | 1 (0) |
| Aggressive | 111 (48) |
| Diffuse large B cell | 44 (19) |
| Peripheral T cell, unspecified | 22 (9) |
| Extranodal NK/T cell, nasal type | 19 (8) |
| Anaplastic large cell | 7 (3) |
| Mantle cell | 5 (2) |
| Others | 14 (6) |
| Lymphoblastic | 84 (36) |
| Precursor B cell | 7 (3) |
| Precursor T cell | 77 (33) |
| Stage I | 9 (4) |
| Stage II | 25 (11) |
| Stage III | 30 (13) |
| Stage IV | 150 (64) |
| No data | 19 (8) |
| Disease characteristics at transplantation | |
| Response to chemotherapy† | |
| Sensitive | 128 (55) |
| Complete remission‡ | 90 (39) |
| Partial remission | 38 (16) |
| Resistant | 104 (45) |
| Primary refractory disease | 41 (18) |
| Refractory relapse | 63 (27) |
| No. of prior chemotherapy regiments† | 3 (0-11) |
| Fewer than 4 regimens | 143 (61) |
| At least 4 regimens | 90 (39) |
| Prior autograft | 40 (17) |
| Prior radiotherapy | 81 (35) |
| Transplantation characteristics | |
| Year of transplantation | |
| 1990-1995 | 46 (20) |
| 1996-2001 | 187 (80) |
| No. of patients receiving a transplant per hospital | |
| Fewer than 9 patients | 146 (63) |
| At least 9 patients | 87 (37) |
| Donor | |
| HLA-matched related | 154 (66) |
| HLA-1 antigen-mismatched related | 19 (8) |
| HLA-matched unrelated | 43 (19) |
| HLA-1 antigen-mismatched unrelated | 17 (7) |
| Donor-recipient sex match | |
| Male-male | 80 (34) |
| Male-female | 66 (28) |
| Female-male | 33 (14) |
| Female-female | 46 (20) |
| Donor-recipient CMV status§ | |
| +/+ | 131 (57) |
| −/+ | 14 (6) |
| +/− | 14 (6) |
| −/− | 11 (5) |
| Source of stem cells | |
| Bone marrow | 159 (68) |
| Peripheral blood cells | 70 (30) |
| Bone marrow + peripheral blood cells | 2 (1) |
| Cord blood | 2 (1) |
| Conditioning regimen | |
| TBI-containing | 193 (83) |
| Non-TBI | 40 (17) |
| GVHD prophylaxis | |
| Cyclosporin + methotrexate | 204 (88) |
| Tacrolimus + methotrexate | 22 (9) |
| Others | 7 (3) |
Variable . | No. (%)* . |
|---|---|
| Patient characteristics | |
| Younger than 40 y | 158 (68) |
| 40 y or older | 75 (32) |
| Male sex | 150 (64) |
| Disease characteristics at diagnosis | |
| Histology | |
| Indolent | 38 (16) |
| Follicular | 37 (16) |
| MALT | 1 (0) |
| Aggressive | 111 (48) |
| Diffuse large B cell | 44 (19) |
| Peripheral T cell, unspecified | 22 (9) |
| Extranodal NK/T cell, nasal type | 19 (8) |
| Anaplastic large cell | 7 (3) |
| Mantle cell | 5 (2) |
| Others | 14 (6) |
| Lymphoblastic | 84 (36) |
| Precursor B cell | 7 (3) |
| Precursor T cell | 77 (33) |
| Stage I | 9 (4) |
| Stage II | 25 (11) |
| Stage III | 30 (13) |
| Stage IV | 150 (64) |
| No data | 19 (8) |
| Disease characteristics at transplantation | |
| Response to chemotherapy† | |
| Sensitive | 128 (55) |
| Complete remission‡ | 90 (39) |
| Partial remission | 38 (16) |
| Resistant | 104 (45) |
| Primary refractory disease | 41 (18) |
| Refractory relapse | 63 (27) |
| No. of prior chemotherapy regiments† | 3 (0-11) |
| Fewer than 4 regimens | 143 (61) |
| At least 4 regimens | 90 (39) |
| Prior autograft | 40 (17) |
| Prior radiotherapy | 81 (35) |
| Transplantation characteristics | |
| Year of transplantation | |
| 1990-1995 | 46 (20) |
| 1996-2001 | 187 (80) |
| No. of patients receiving a transplant per hospital | |
| Fewer than 9 patients | 146 (63) |
| At least 9 patients | 87 (37) |
| Donor | |
| HLA-matched related | 154 (66) |
| HLA-1 antigen-mismatched related | 19 (8) |
| HLA-matched unrelated | 43 (19) |
| HLA-1 antigen-mismatched unrelated | 17 (7) |
| Donor-recipient sex match | |
| Male-male | 80 (34) |
| Male-female | 66 (28) |
| Female-male | 33 (14) |
| Female-female | 46 (20) |
| Donor-recipient CMV status§ | |
| +/+ | 131 (57) |
| −/+ | 14 (6) |
| +/− | 14 (6) |
| −/− | 11 (5) |
| Source of stem cells | |
| Bone marrow | 159 (68) |
| Peripheral blood cells | 70 (30) |
| Bone marrow + peripheral blood cells | 2 (1) |
| Cord blood | 2 (1) |
| Conditioning regimen | |
| TBI-containing | 193 (83) |
| Non-TBI | 40 (17) |
| GVHD prophylaxis | |
| Cyclosporin + methotrexate | 204 (88) |
| Tacrolimus + methotrexate | 22 (9) |
| Others | 7 (3) |
The study included 233 patients. The median age was 31 years (range, 15-59 years). Age was a continuous variable.
MALT indicates extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue; NK, natural killer; HLA, human leukocyte antigen; CMV, cytomegalovirus; TBI, total body irradiation; GVHD, graft-versus-host disease.
Categoric variable.
One patient with mediastinal B-LBL did not receive prior chemotherapy for an unknown reason but did receive prior radiotherapy.
Includes 2 patients in complete remission, unconfirmed.
Sixty-three pairs were not evaluated for CMV status.